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The HIV coreceptor CCR5 is a validated target for
both the prevention and therapy of HIV infection. PSC-
RANTES, an N-terminally modified analogue of one of the
natural chemokine ligands of CCR5 (RANTES/CCL5), is a
potent inhibitor of HIV entry into target cells. Here, we set
out to engineer the anti-HIV activity of PSC-RANTES into
another natural CCR5 ligand (MIP-1b/CCL4), by grafting
into it the key N-terminal pharmacophore region from
PSC-RANTES. We were able to identify MIP-1b/CCL4
analogues that retain the receptor binding profile of MIP-
1b/CCL4, but acquire the very high anti-HIV potency and
characteristic inhibitory mechanism of PSC-RANTES.
Unexpectedly, we discovered that in addition to N-terminal
structures from PSC-RANTES, the side chain of Lys33 is
also necessary for full anti-HIV potency.
Keywords: CCR5/HIV coreceptor/MIP-1b CCL4/
pharmacophore grafting/PSC-RANTES
Introduction
HIV requires a two-step interaction with the host cell in order
to gain entry and initiate infection. Interaction with CD4 leads
to a conformational change in the HIV envelope complex
allowing a subsequent interaction with a coreceptor (Berger
et al., 1999). Although a number of different chemokine
receptors have shown coreceptor activity in vitro, it is probable
that only two, CCR5 and CXCR4, are of physiological rel-
evance (Moore et al., 2004). While infected persons generally
harbor both CCR5 and CXCR4-utilizing strains of HIV (R5
and X4 strains), only R5 strains are involved to a significant
extent in person-to-person transmission of the disease, and
homozygotes for an inactivating CCR5 allele show a remark-
able degree of protection from HIV acquisition. Hence, target-
ing R5-tropic viruses is a promising HIV prevention strategy
(Lederman et al., 2006) as well as an additional option for
HIV therapy (Maeda et al., 2004).
While the native chemokine ligands of CCR5, MIP-1a/
CCL3, MIP-1b/CCL4, RANTES/CCL5 and MCP-2/CCL8
(Cocchi et al., 1995; Blanpain et al., 1999) are capable of
blocking entry of R5 tropic strains, several N-terminally modi-
fied variants of these proteins with enhanced inhibitory potency
have been identified (Oravecz et al., 1997a; Simmons et al.,
1997; Polo et al., 2000; Hartley et al., 2003, 2004). The more
potent of these molecules apparently share a novel inhibitory
mechanism involving the induction of prolonged intracellular
sequestration of CCR5 (Hartley et al., 2005). PSC-RANTES
(Hartley et al., 2004) is the most potent molecule of this type to
have been identified so far, and has shown potential for use
both in HIV therapy (Hartley et al., 2004) and as a topical HIV
prevention agent (Lederman et al., 2004).
All chemokines for which structures have been determined
share a characteristic tertiary structure that consists of a
highly structured core domain from which extends a flexible
N-terminal region [reviewed in (Fernandez et al., 2002)]. The
current model for chemokine structure-activity involves a
two-site ‘message-address’ docking mechanism (Siciliano
et al., 1994; Wells et al., 1996), which has been characterized
in detail for RANTES/CCL5 (Blanpain et al., 2002). The
core region carries ‘address’ structures with which receptors
are initially engaged with high affinity and specificity, and
then the N-terminal region, carrying ‘message’ structures,
induces the subsequent receptor activation [reviewed in
(Fernandez et al., 2002)].
According to this model, the enhanced anti-HIV potency
of N-terminally modified chemokine analogues like PSC-
RANTES would relate to changes in ‘message’ activity,
influencing receptor modulation, rather than ‘address’ struc-
tures involved in specificity and affinity of receptor binding.
Indeed, PSC-RANTES exhibits CCR5 binding affinity that is
not significantly different to that of native RANTES/CCL5,
and its increased anti-HIV potency does appear to be corre-
lated with an effector function: capacity to induce intracellu-
lar sequestration of CCR5 (Hartley et al., 2004).
We therefore established a working hypothesis in which
it would be possible to graft the pharmacophore region
of PSC-RANTES onto another chemokine, giving it the
capacity to induce the ‘message’ function, i.e. capacity to
induce intracellular sequestration of CCR5, without altering
its ‘address’ function, i.e. receptor specificity and affinity.
We chose to test this hypothesis using MIP-1b/CCL4, a che-
mokine which is generally recognized (Bacon et al., 2002) as
having a narrower receptor binding profile (CCR5 alone)
than RANTES/CCL5 (CCR5 plus CCR1 and CCR3), since
engagement of the latter two receptors is neither a necessary
nor a desirable property for HIV entry inhibitors.
Materials and methods
Chemical synthesis of chemokines
The chemokines and chemokine analogues used in this study
were prepared by total chemical synthesis as previously
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described (Wilken et al., 1999; Hartley et al., 2004). Briefly,
N-terminal and C-terminal fragments were synthesized using
Boc chemistry, assembled using Native Chemical Ligation
(Dawson et al., 1994) and refolded under conditions promot-
ing the formation of disulfide bridges. The purity and integ-
rity of each sample was verified by hplc and mass
spectrometry.
R5-tropic envelope-dependent cell fusion assay
The anti-HIV potency of the chemokine analogues was
determined using a cell fusion assay as described previously
(Hartley et al., 2003, 2004).
Competition binding assays
Competition binding experiments on CCR5 were performed
as described previously (Hartley et al., 2003, 2004). For
CCR1 and CCR3, experiments were performed on membrane
preparation made from cells expressing CCR1 or CCR3,
using 0.2 nM 125I-MIP-1b or 125I-Eotaxin (Amersham) as
labeled tracers, and variable concentrations of chemokines as
unlabeled competitors. Samples were incubated for 60 min at
278C, and then bound tracer was separated by filtration
through GF/B filters presoaked in 0.5% BSA. Filters were
counted in a g-scintillation counter. Binding parameters were
determined with Prism software (GraphPad) using non-linear
regression applied to a single-site binding model.
CCR5 downmodulation assay
The capacity of chemokine analogues to induce CCR5 down-
modulation was adapted from flow cytometry-based tech-
niques (Hartley et al., 2003, 2004; Pastore et al., 2003)
to enable measurements to be made in 96-well plates.
CHO-CCR5 cells were seeded at a density of 80 000 cells/
well. After overnight incubation, medium was removed and
replaced with medium containing chemokine analogues at
different concentrations and cells were incubated for 1 h at
378C. Medium was then removed and cells were fixed with
4% paraformaldehyde and washed twice with PBS. Cells were
then labeled with either phycoerythrin-conjugated anti-CCR5
antibody (clone 3A9, Pharmingen) or phycoerythrin-
conjugated anti-CCR1 antibody (clone 53 504, R&D systems;
negative control) in PBS supplemented with 1% BSA
(PBS-1% BSA) on ice for 1 h. Plates were washed three
times with PBS-1% BSA and fluorescence values for each
well were determined using a FLEXstation fluorimeter
(Molecular Devices). Results are expressed as % control level
of surface CCR5: 100  [mean fluorescence (chemokine
added, anti-CCR5)2mean negative control fluorescence
(anti-CCR1)]/[mean positive control fluorescence (no chemo-
kine added, anti-CCR5)2mean fluorescence (anti-CCR1)].
Ca2+ flux assays
Ca2+ flux assays on CCR5-expressing cells were performed
essentially as described previously (Hartley et al., 2003) using
96-well plates and a FLEXstation fluorimeter (Molecular
Devices). Fluorescence measurements were carried out on
HeLa-P5L cells (Simmons et al., 1997) loaded with Fluo-4
(Molecular Probes) according to the manufacturer’s rec-
ommendations and maintained at 378C. Baseline measure-
ments were recorded during 15 s prior to chemokine addition,
after which fluorescence peaks corresponding to intracellular
Ca2+ fluxes were measured over a further 60 s. Signals were
quantified using the ‘area under curve’ function in the
SoftMax software (Molecular Devices), and expressed in
relative fluorescence units. Measurements were performed in
duplicate. Responses on CHO-K1 cells expressing either
CCR1 or CCR3 were measured in an aequorin-based assay
as previously described (Blanpain et al., 1999). Dose-
response curves were fitted to the data using Prism software
(GraphPad) using non-linear regression applied to a sigmoi-
dal dose-response model.
Results
Engineering potent anti-HIV activity into MIP-1b/CCl4: first
generation
We began by designing a set of PSC-RANTES-MIP-1b/
CCL4 chimeras in which N-terminal fragments of increasing
size were grafted from PSC-RANTES into MIP-1b/CCL4,
replacing the residues at the corresponding position in the
sequence (Table I). These proteins were assayed for their
anti-HIV potency in an R5-tropic envelope-dependent cell
fusion assay (Table I). The potencies of both unmodified
RANTES/CCL5 and MIP-1b/CCL4 were too low to be accu-
rately determined over the concentration range used, but in
previous experiments using the same assay we have found
these molecules to have IC50 values of in the low micromolar
range (unpublished results). These values indicate potencies
lower than those published in other studies that used viral
replication assays on T-cell-derived cell lines (e.g. (Oravecz
et al., 1997b)), and we stress that the cell fusion assay was
used in this study to provide relative, rather than absolute
potency values. In this respect, previous work has shown that
it is both highly reproducible and predictive of results
obtained in replication assays using primary cells and
CCR5-tropic HIV-1 strains (Hartley et al., 2003, 2004). An
IC50 value of 40 pM for PSC-RANTES, in agreement with
previously published work (Hartley et al., 2004). Simply
substituting the PSC-RANTES moiety (n-nonanoyl-
hioprolyl-cyclohexylglycyl-) for the corresponding part of
MIP-1b/CCL4 (Ch1-MIP-1b) did not lead to a significant
gain in potency. On the other hand, molecules in which a
few more residues of MIP-1b/CCL4 were replaced by the
corresponding residues from the N-terminal region of
PSC-RANTES (Ch2-MIP-1b through Ch6-MIP-1b) showed
potencies that were significantly improved (IC50 values in the
range 60–300 nM), although still modest compared to that of
PSC-RANTES (40 pM). Moving the junction between the
sequence derived from PSC-RANTES and that derived from
MIP-1b/CCL4 to the middle of the primary structure (i.e.
to the third conserved cysteine residue, Ch7-MIP-1b) led to
a striking increase in potency (IC50 value of 100 pM, i.e.
only 2.5-fold less potent than PSC-RANTES). Comparison
between the potencies of Ch6-MIP-1b (in which the junction
point was moved a little nearer the N-terminus) and Ch7-
MIP-1b suggests that key structures for inhibitory activity
are located between positions 26 and 33 of PSC-RANTES.
Engineering potent anti-HIV activity into MIP-1b/CCL4:
second generation
Noting the proximity of the side chain of Lys33 to the
N-terminal region of RANTES in the available 3D structures
(Fig. 1), we postulated that the side chain of Lys33 might be
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a key structure for potent anti-HIV activity, and this led us to
design a second series of proteins to test the hypothesis
(Table II). We substituted Lys33 of PSC-RANTES with
leucine (PSC K33L), the residue at the corresponding pos-
ition of MIP-1b/CCL4, which led to a loss in potency of
approximately 1000-fold. Making the reverse switch, of
leucine to lysine, at this position in the context of protein
Ch2-MIP-1b from the first set of molecules, led to a
200-fold increase in potency (Ch8-MIP-1b; IC50 value of
300 pM, i.e. 8-fold less potent than PSC-RANTES). The
leucine-to-lysine switch alone in MIP-1b/CCL4 did not lead
to a detectable increase in potency (MIP-1b/CCL4L34K),
however. Hence Lys33 is a key structure for the anti-HIV
activity of PSC-RANTES, and is needed in combination with
the structures derived from the N-terminal region of
PSC-RANTES in order to confer maximal anti-HIV potency
on MIP-1b/CCL4.
Structure-activity relationships at position 33
The key role played by the side chain at the position corre-
sponding to Lys33 in RANTES/CCL5 on the anti-HIV
activity of both PSC-RANTES and the MIP-1b/CCL4 ana-
logues prompted us to investigate the manner in which struc-
tures at this position might influence the anti-HIV activity of
the chemokines. The anti-HIV activity mechanism of both
natural chemokines and chemokine analogues [reviewed in
(Hartley et al., 2005)] has been linked to (i) steric blockade
of cell surface CCR5 binding sites and (ii) induction of intra-
cellular CCR5 sequestration, which has been argued to be
dependent upon CCR5 agonist activity through the engage-
ment of cellular processes linked to homologous receptor
desensitization (Oppermann et al., 1999). We therefore chose
to study the influence of the Lys33 structure on CCR5
binding affinity, capacity to induce CCR5 downmodulation
and capacity to elicit CCR5 signaling.
CCR5 binding affinity. CCR5-binding affinity was compared
in a competition binding assay on CHO-CCR5 cells using
125I MIP-1b/CCL4 as a tracer (Fig. 2). In agreement with
previously published work (Hartley et al., 2004), we found
Table I. Primary sequence and anti-HIV activity of a group of PSC-RANTES/MIP-1b/CCL4 chimera proteins
ZXX indicates the n-nonanoyl-thioprolyl-cyclohexylglycyl moiety of PSC-RANTES. Sequences derived from RANTES/CCL5 are boxed in gray; sequences
derived from MIP-1b/CCL4 are indicated in plain text; sequences shared by the two chemokines are boxed in black. Anti-HIV potency (IC50) was determined
in an R5-tropic envelope-dependent cell fusion assay.
Fig. 1. Three-dimensional structure of the most likely configuration in
solution of a RANTES monomer as determined by homonuclear NMR
spectroscopy [1RTN (Skelton et al., 1995)], indicating the proximity of the
side chain of Lys33 (indicated in mauve) to the N-terminal region (residues
1–9, indicated in yellow). Coloring elsewhere in the protein follows the
CPK convention. This illustration was generated using RasMol (Sayle et al.,
1995).
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that RANTES and PSC-RANTES have comparable affinity
for CCR5. While the K33L variant of PSC-RANTES (PSC
K33L) has an apparent affinity approximately 5-fold lower
than PSC-RANTES, substitution of lysine into either
MIP-1b/CCL4 (MIP L34K) or the N-terminally modified
analog, Ch2-MIP-1b (Ch8-MIP-1b), did not lead to a signifi-
cant gain in affinity. Broadly similar results were obtained
using 125I RANTES/CCL5 as a tracer (data not shown).
Hence Lys33 might make some contribution to receptor
binding affinity, but not enough to account for either the
1000-fold loss in anti-HIV potency when it is replaced by
leucine in PSC-RANTES (PSC K33L), or the 200-fold
increase in potency when it is engineered into the MIP-1b/
CCL4 analogue Ch2-MIP-1b (Ch8-MIP-1b). Finally, as was
previously seen across a panel of RANTES analogues
(Hartley et al., 2004), no correlation between anti-HIV
potency and receptor (CCR5) binding affinity was seen
across this group of chemokines.
CCR5 sequestration. Capacity to induce intracellular CCR5
sequestration was compared using a steady-state receptor
downmodulation assay carried out on CHO-CCR5 cells.
PSC-RANTES and Ch8-MIP-1b clearly exhibit a greater
capacity to induce CCR5 downmodulation than the corr-
esponding lysine-to-leucine analogues, PSC K33L and
Ch2-MIP-1b (Fig. 3). As was previously seen across a panel
of RANTES analogues (Hartley et al., 2004), the rank order
of anti-HIV potency across this group of molecules
(PSC-RANTES, Ch8-MIP-1b  Ch2-MIP-1b, PSC K33L;
Table II) correlates with their capacity to induce CCR5
downmodulation.
CCR5 signaling. CCR5 signaling capacity was tested in a
Ca2+ flux assay in Hela-P5L cells (Fig. 4). In this assay,
PSC-RANTES is clearly a CCR5 superagonist—it is both a
more potent and a more efficacious agonist than native
RANTES/CCL5 (Fig. 4A). This property has been observed
for several other RANTES analogues with potent anti-HIV
activity and the capacity to induce intracellular sequestration
of CCR5 (Hartley et al., 2003). While inclusion of key
N-terminal structures from PSC-RANTES is sufficient to
create a superagonist from MIP-1b/CCL4 (Ch2-MIP-1b), a
further increase in signaling activity is gained through
inclusion of Lys33 (Ch8-MIP-1b). In the same way, substi-
tution of Lys33 for leucine in PSC-RANTES leads to a
reduction in signaling activity (Fig. 4B). The rank order of
signaling activity of the analogues in this assay correlates
Table II. Primary sequence and anti-HIV activity of a second group of PSC-RANTES/MIP-1b/CCL4 chimera proteins
ZXX indicates the n-nonanoyl-thioprolyl-cyclohexylglycyl moiety of PSC-RANTES. Sequences derived from RANTES/CCL5 are boxed in gray; sequences
derived from MIP-1b/CCL4 are indicated in plain text; sequences shared by the two chemokines are boxed in black.
Fig. 2. CCR5 binding affinity of chemokines. Apparent binding affinities
(pIC50) were determined in a competition binding assay using CHO-CCR5
cells and radioiodinated MIP-1b/CCL4 as a tracer. Bars indicate mean pIC50
values from two independent experiments, error bars indicate SEM. Fig. 3. Capacity of chemokine analogues to elicit CCR5 downmodulation
on CHO-CCR5 cells. Cells seeded in multiwell plates were incubated with
chemokines at 30 nM for 1 h with prior to quantification of cell surface
CCR5. Bars represent mean cell surface CCR5 levels (% control)+SEM
(n = 6).
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with the rank order of activity in the CCR5 downmodulation
assay, with PSC-RANTES and Ch8-MIP-1b clearly stronger
agonists than Ch2-MIP-1b and PSC K33L.
Receptor selectivity
According to our working hypothesis, analogues with modifi-
cations occurring in the ‘message’ region of the protein
would retain the receptor-binding profile (a function carried
by the ‘address’ structures) of the parent chemokines. Since
RANTES/CCL5 is known to activate CCR1 and CCR3 in
addition to CCR5, whereas MIP-1b/CCL4 is generally
recognized as a CCR5-selective chemokine, we were able to
test this hypothesis using binding assays and functional
assays on CCR1 and CCR3.
Competition binding assays on CCR1 and CCR3. Binding
affinities were determined in competition binding assays on
CHO-K1 cells expressing either CCR1 or CCR3 and using
either radio-iodinated MIP-1a/CCL3, RANTES/CCL5 or
Eotaxin/CCL11 as tracers (Table III).
The binding affinities for the recognized natural ligands of
CCR1, MIP-1a/CCL3 and RANTES/CCL5 were similar to
previously published values (Neote et al., 1993), and
PSC-RANTES exhibited comparable CCR1 binding affinity
to the parent chemokine, RANTES/CCL5.
In contrast to its generally accepted description as a
CCR5-selective ligand [e.g. (Bacon et al., 2002)], we found
MIP-1b/CCL4 to be a high affinity CCR1 ligand. Its appar-
ent affinity (IC50 value of 11.0 nM+ 3.5) lies between that
of MIP-1a/CCL3 (IC50 value of 0.2 nM+ 0.1) and that of
RANTES/CCL5 (IC50 value of 29.5 nM+ 12.4). We
measured similarly high CCR1 binding affinities for both
Ch2-MIP-1b and Ch8-MIP-1b (IC50 values of 9.6+ 3.2 nM,
and 2.5+ 0.2 nM, respectively).
With regard to CCR3 binding affinity, while the apparent
binding affinity that we obtained for Eotaxin/CCL11 (IC50
value of 0.4+ 0.2) is comparable to previously published
values (Daugherty et al., 1996; Ponath et al., 1996), we were
unable to detect any binding activity for native RANTES/
CCL5 when 125I Eotaxin/CCL11 was used as a tracer
(Table III). In this respect, our results were similar to those
of Ponath et al., who found RANTES/CCL5 gave barely
detectable competition (IC50. 100 nM) for CCR3 binding
on both primary eosinophils and a transfected cell line. We
were also unable to generate usable CCR3 binding data
using 125I RANTES/CCL5 as a tracer (data not shown).
None of the other native chemokines and chemokine ana-
logues that were tested showed any detectable competition in
CCR3 binding assays. Given that we were unable to detect
competition using RANTES/CCL5 as a competitor, we
cannot exclude the possibility that some or all of these mol-
ecules bind to CCR3, but that binding activity is not detect-
able in this assay.
Signaling assays on CCR1 and CCR3. Signaling assays were
carried out in CHO-K1 cells expressing either CCR1 or
CCR3 (Fig. 5A and B). In agreement with previously pub-
lished work (Neote et al., 1993), we found both RANTES/
CCL5 and MIP-1a/CCL3 to be potent CCR1 agonists
(Fig. 5A). PSC-RANTES behaves as a very weak partial
Table III. Binding affinity of chemokines on CCR1 and CCR3
Molecule CCR1 IC50 (nM) CCR3 IC50 (nM)
125I MIP-1a/
CCL3
125I RANTES/
CCL5
125I Eotaxin/
CCL11
MIP-1a/CCL3 0.2+0.1 0.3+0.1 n.d.
MIP-1b/CCL4 11.0+3.5 n.d. n.d.
RANTES/CCL5 29.5+12.4 8.1+5.7 .100
Eotaxin/CCL11 n.d. n.d. 0.4+0.2
PSC-RANTES 4.3+1.0 5.0+1.9 .100
Ch2-MIP-1b 9.6+3.2 n.d. .100
Ch8-MIP-1b 2.5+0.2 n.d. .100
Competition binding assays were carried out on CHO-K1 cells expressing
CCR1 or CCR3 using 125I MIP-1a/CCL3, 125I RANTES/CCL5 or 125I
Eotaxin/CCL11 as tracers. The data were normalized for non-specific
binding (0%), determined in the presence of 300 nM unlabelled control
competitor (MIP-1a/CCL3 for CCR1; Eotaxin/CCL11 for CCR3), and
specific binding (100%) in the absence of competitor. IC50 values were
determined by non-linear regression using the GraphPad Prism software
applied to a single site model.
Fig. 4. Signaling activity on CCR5. The signaling capacity of chemokines
was determined using a calcium flux assay on Hela-P4-CCR5 cells. Cells
growing in multiwell plates were loaded with Fluo-4 and peak fluorescence
measurements (relative fluorescence units) were made after addition of
chemokines. Each data point was measured in duplicate (error bars indicate
SEM). The displayed data are representative of at least three independent
experiments. (A) Comparison of the signaling activity of PSC-RANTES (B)
with that of the native ligand, RANTES/CCL5 (P). (B) Lys33 and CCR5
signaling activity. Comparison of the signaling activity of PSC-RANTES
(B) and native MIP-1b/CCL4 (S) with that of the analogues PSC(K33L)
(A), Ch2-MIP-1b (W) and Ch8-MIP-1b (†).
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agonist on CCR1. In spite of its high binding affinity
(Table III), MIP-1b/CCL4 has no detectable signaling
activity on CCR1. Similarly, neither Ch2-MIP-1b nor
Ch8-MIP-1b showed any detectable signaling activity on
CCR1.
In the CCR3 signaling assay (Fig. 5B), we found Eotaxin/
CCL11 to be a potent and efficacious agonist, with
RANTES/CCL5 a less potent partial agonist. These results
are in agreement with previously published studies
(Daugherty et al., 1996; Ponath et al., 1996); the detection of
signaling activity of RANTES/CCL5 in this assay indicates
that our inability to detect binding of RANTES to CCR3 in
the competition binding assay (Table III) was due to limit-
ations of the assay system rather to problems with either the
cell line or the ligands used. MIP-1b/CCL4 did not show
any detectable CCR3 activation at any concentration tested,
neither did PSC-RANTES or the MIP-1b/CCL4 analogues,
Ch2-MIP-1b and Ch8-MIP-1b. Given our limited ability to
detect CCR3 binding in the competition binding assay, there
are two possible explanations for this result: either (i) the
molecules do not engage CCR3 at all, or (ii) they engage the
receptor without eliciting a signal.
Discussion
Generating a potent HIV inhibitor based on MIP-1b/CCL4
We set out with a working model under which it should have
been possible to engineer potent anti-HIV activity into
MIP-1b/CCL4 by grafting on the N-terminal pharmacophore
from PSC-RANTES. While it was possible to attain modest
improvements in potency by grafting in the PSC moiety
(n-nonanoyl-thioprolyl-cyclohexylglycyl-) plus some adjacent
N-terminal residues (Ch2-MIP-1b through Ch6-MIP-1b),
it was necessary to include Lys33 (Ch8-MIP-1b), a residue that
is located towards the middle of the primary sequence
of RANTES/CCL5 and its derivatives, in order to reach levels
of anti-HIV potency comparable to that of PSC-RANTES.
Hence, it would appear that the key anti-HIV pharmacophore
from PSC-RANTES includes not only the PSC moiety itself,
but also Lys33 and one or more of residues 4–8 from the
RANTES/CCL5 sequence. In spite of its separation from the
N-terminal region in the primary sequence of RANTES/CCL5,
the Lys33 side chain is in close proximity to the N-terminal
region in 3-D structures of both RANTES/CCL5 (Fig. 1) and
RANTES analogues for which structural data are available
(not shown). A previous study has implicated structures in the
‘N-loop’ and ‘310 turn’ region of MIP-1b/CCL4 (correspond-
ing to residues 12–23 in Table I) as important for interaction
with CCR5 (Bondue et al., 2002). We did not observe major
differences in anti-HIV activity for analogues in which part or
all of this region was replaced by the corresponding region
from RANTES/CCL5 (analogues Ch3-MIP-1b through
Ch6-MIP-1b in Table I). This may be because the structure
from the RANTES ‘N-loop’ and ‘310 turn’ region is capable of
fulfilling the CCR5-binding function carried by the corre-
sponding region from MIP-1b/CCL4. In this respect, we note
that there are many identical residues in the primary sequence
alignment for the two chemokines in this region (Table I).
We have previously shown that optimization of the
anti-HIV activity of RANTES/CCL5 analogues including
PSC-RANTES is not related to a gain in affinity for CCR5,
instead it relates to increasing the capacity of the molecules
to induce intracellular sequestration of CCR5 (Hartley et al.,
2004). The results of this study, involving optimization of
the anti-HIV activity of MIP-1b/CCL4 analogues by grafting
in the anti-HIV pharmacophore from PSC-RANTES are also
consistent with an inhibitory mechanism involving intracellu-
lar sequestration of CCR5.
A structure close to the core domain of PSC-RANTES which
is crucial for anti-HIV potency
In this study, we demonstrate that Lys33 is a key constituent
of the anti-HIV pharmacophore from PSC-RANTES: sub-
stitution of Lys33 for leucine, the corresponding amino acid
from MIP-1b/CCL4, resulted in a 1000-fold reduction in
potency, and making the corresponding leucine-to-lysine
exchange at this position in the context of the most potent
N-terminally modified variant of MIP-1b/CCL4 (Ch2-
MIP-1b) led to a 200-fold gain in potency (Ch8-MIP-1b,
Table II). The identification of a role for these additional
positions, 4–8 and 33, has permitted us to take them into
account in the further optimization of PSC-RANTES and
related molecules (Gaertner et al., 2008).
Lys33 has been previously identified as a residue that plays
a key role in the interaction of native RANTES/CCL5 with
Fig. 5. Signaling activity on RANTES receptors. Functional responses were
measured using the aequorin-based functional assay (Blanpain et al., 1999).
Cells were incubated with a range of concentrations of chemokines as
indicated in the legend, and luminescence (RLU) was recorded for 30 s.
Each data point was measured in duplicate (error bars indicate SEM). The
displayed data are representative of three independent experiments. (A)
CCR1; (B) CCR3.
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CCR5 (Martin et al., 2001). The proximity of its side chain
to the N-terminal region of the protein suggests that it could
readily participate in either intra- or intermolecular inter-
actions that are key to receptor engagement, and it has been
suggested that the position corresponding to Lys33 in some
other chemokines might play an important role in receptor
engagement [Eotaxin-1/CCL11, MCP-3/CCL7; (Fernandez
et al., 2000)]. However, structure-activity studies carried out
on IL-8/CXCL8 (Clark-Lewis et al., 1994) and SDF-1/
CXCL12 (Ueda et al., 1997) have shown that the residue in
this position can be substituted for alanine without any
impact on biological activity for certain other chemokines.
Lys33 and the ‘two-site’ model for the interaction between
chemokines and their receptors
According to the ‘two-site’ model for the interaction
between chemokines and their receptors, ‘message’ structures
are generally located in the flexible N-terminal region of
the proteins, with ‘address’ structures located further into the
primary sequence, predominantly in the N-loop region
(Fernandez et al., 2002). Skelton et al. (Skelton et al., 1995)
used proton NMR to determine the 20 most likely structures
of RANTES in solution. Comparison of these structures
shows that the first three residues do indeed represent an
extremely flexible part of the chain, while Lys33, which is
located neither in the N-terminal region nor in the N-loop
region, is not in a particularly flexible part of the structure
(Fig. 6A). It is possible that Lys33 interacts with the
N-terminal sequence through a hydrogen bond between its
e-NH3
+ and the main chain carbonyl group of Ser4 (Fig. 6B).
Ser4 is already in a much less flexible region than the three
residues that precede it. It is probably legitimate to extrap-
olate from the RANTES structure to that of PSC-RANTES,
as both X-ray and NMR determinations of the structures of a
number of N-terminally modified RANTES derivatives all
show the same general features [AOP-RANTES, (Wilken
et al., 1999); Met-RANTES, (Hoover et al., 2000)].
Lys33 does not appear to act as an ‘address’ structure.
While there is some evidence of an effect on CCR5 binding
affinity shown by the 10-fold loss in apparent affinity
between PSC-RANTES and the modified analogue PSC
K33L (Fig. 2), this is not sufficient to account for the striking
effects on anti-HIV activity (Table II), and the analogous
leucine–lysine exchange which provides Ch8-MIP-1b with a
200-fold improvement in anti-HIV potency over
Ch2-MIP-1b (Table II) is not accompanied by any detectable
change in CCR5 affinity (Fig. 2).
Instead, Lys33 appears to act as a ‘message’ structure, or to
stabilize a favorable conformation of that structure. Inclusion
of Lys33 significantly increases the capacity of the chemokines
in this study to elicit effector functions—both CCR5 downmo-
dulation (Fig. 3) and CCR5 signaling (Fig. 4B). There is some
evidence to suggest that Lys33 may also function as a
‘message’ structure in native RANTES/CCL5: a previously
published study (Martin et al., 2001) showed that acetylation
of Lys33 almost completely abrogates the capacity of
RANTES to signal via CCR5.
MIP-1b/CCL4: a high affinity CCR1 ligand
Although MIP-1b/CCL4 is often cited in the literature as a
CCR5-specific chemokine (Ward et al., 1998; Murdoch et al.,
2000; Thelen et al., 2001; Bacon et al., 2002), we (this study)
and others (Neote et al., 1993; Ben-Baruch et al., 1995; Sarau
et al., 1997; Chou et al., 2002) have found it to be a high-
affinity CCR1 ligand. We suspect that the frequent designation
of MIP-1b/CCL4 as an exclusively CCR5-selective chemo-
kine relates to its lack of signaling activity on CCR1: MIP-1b/
CCL4 is only functionally selective for CCR5 (Figs 4B, 5A
and B). Since MIP-1b/CCL4 has no signaling activity on
CCR1 but has a high affinity for the receptor, the suggestion
has been made that it may have a physiological role as a
CCR1 antagonist (Chou et al., 2002).
Signaling activity of PSC-RANTES on RANTES receptors
In this study, we present the first data concerning the signal-
ing activity of PSC-RANTES. As has previously been seen
for other N-terminally modified RANTES analogues that
induce intracellular CCR5 sequestration (Hartley et al.,
2003), PSC-RANTES is a CCR5 superagonist. On the other
hand, while PSC-RANTES is a high affinity ligand of CCR1
(Table III), it is only a weak partial agonist, where native
RANTES/CCL5 is a full agonist on this receptor (Fig. 5A),
and unlike native RANTES/CCL5, PSC-RANTES has no
detectable signaling activity on CCR3 (Fig. 5B). Reduction
in signaling activity on CCR1 and CCR3 has been seen for
several other N-terminally modified RANTES analogs with
enhanced anti-HIV activity (Elsner et al., 2000; Hartley
et al., 2003). It is possible that modifications that enhance
Fig. 6. (A) A stereo-view superimposition of the 20 most likely solution
structures of RANTES as determined by homonuclear nmr spectroscopy
(Skelton et al., 1995). Only the configurations adopted by the main chain are
shown (grey) together with the configurations adopted by the side chains of
residue Ser-4 (cyan) and Lys-33 (mauve). Note the extreme mobility of the
main-chain parts of residues 1–3 (shown at the top of the image). (B) A
closer view of the potential interaction between the e-NH3
+ of Lys-33 and
the oxygen of the backbone carbonyl of Ser-4. The positions of the centers
of these two atoms in the 20 most likely structures are shown as small blue
and red spheres, respectively. Other graphic conventions are as in A. This
illustration was generated using RasMol (Sayle et al., 1995).
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CCR5 engagement are not compatible with agonist activity
on CCR1 and CCR3.
Ch8-MIP-1b: a new chemokine analogue with highly potent
anti-HIV activity and narrowed receptor selectivity
Since engagement of receptors other than CCR5 is unnecess-
ary for HIV inhibition, and could be undesirable, the goal of
this study was to develop a new chemokine analogue with
both (i) highly potent anti-HIV activity and (ii) receptor
specificity narrowed to CCR5 alone. In Ch8-MIP-1b, we
were able to identify a MIP-1b/CCL4 analogue with potency
comparable to that of PSC-RANTES, and which retains the
receptor binding profile of MIP-1b/CCL4. This means that
Ch8-MIP-1b is not a CCR5-specific ligand, however; like
native MIP-1b/CCL4, it is a high affinity CCR1 ligand
(Table III) without functional consequences that we have
been able to detect.
Conclusion
In previous work, we have described the technique of
‘protein medicinal chemistry’ as a way to identify and opti-
mize key pharmacophore regions in proteins through the
rational incorporation of non-natural, non-coded structures
(Hartley et al., 2004). In this study, we have shown that it is
possible to graft such a pharmacophore region from a
‘donor’ protein to a related ‘recipient’ protein, conferring on
the recipient protein the optimized characteristics of the
donor protein. In doing so, we discovered that the key phar-
macophore from PSC-RANTES, a highly potent anti-HIV
molecule (Hartley et al., 2004, Lederman et al., 2004),
extends beyond the N-terminal PSC moiety to include one or
more residues adjacent to it in the sequence, plus the side
chain of Lys33. This new information could be usefully
applied to the further optimization of anti-HIV molecules
based on chemokines.
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